# Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers

> **NCT07370155** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Ashvattha Therapeutics, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MGB 200 mg
- **DRUG:** MGB 400 mg
- **DRUG:** MGB 600 mg

## Key facts

- **NCT ID:** NCT07370155
- **Lead sponsor:** Ashvattha Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2026-05-13
- **Final completion:** 2026-06-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07370155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07370155, "Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07370155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*